Meanwhile, in another study, Song et al [20] found that the median PFS was 5.6 and 10.7 months for EGFR-TKI-treated NSCLC patients with rapid and slow progression, respectively. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.